anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being "on-treatment" for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is "Yes" or "further assessment required," the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm.
On Day 1 subjects are dosed with 100 µg of PRX-P4-003 and PK samples are drawn according to protocol. The treatment will be administered under the fed condition.
The present invention relates to a scented candle. More specifically, the scented candle implements aromatherapy effects gradually in the adjacent space when the wick is ignited and burns while generating liquid aromatic massage oil at 38-39 degrees in the area around the fixed wick to apply the massage oil whose temperature is elevated to skin instantly and effectively. According to the present invention, the scented candle includes a bottle and the wick vertically arranged in the wick. Beeswax, grape seed oil, jojoba oil, olive oil, grapefruit peel oil, and lemon oil are filled and solidified in the bottle. With respect to the total weight of the filling, the filling of the bottle includes: 53-57 wt% of the beeswax; 20-26 wt% of the grape seed oil; 5-11 wt% of the jojoba oil; 3-9 wt% of the olive oil; and 2-5 wt% of the grapefruit peel oil; and 3-5 wt% of the lemon oil. The present invention implements the aromatherapy effects gradually in the adjacent space when the wick is ignited and burns and generates the liquid aromatic massage oil at 38-39 degrees in the area around the fixed wick to apply the massage oil whose temperature is elevated to the skin instantly.
IMM-124E (Travelan) is the investigational product. Travelan 1200mg will be taken orally for 7 days.
ETHNOPHARMACOLOGICAL RELEVANCE: Gout is a crystal-related arthropathy caused by monosodium urate (MSU) deposition, resulting from purine metabolism disorders and hyperuricemia (HUA). Gout belongs to the traditional medicine category of Bi syndrome. Biqi capsules (BQ) is a traditional Chinese medicine formula used to treat Bi syndrome. The BQ prescription is derived from the ancient prescription of Hua Tuo, a famous physician in the Han Dynasty.
AIM OF THE STUDY: To study the effect and mechanism of BQ in treating acute gouty arthritis (AGA) and HUA.
MATERIALS AND METHODS: Analyzing BQ's signaling pathways for gout treatment via network pharmacology. The HUA model was induced orally with adenine and potassium oxonate. The rat AGA model was established by MSU injection. In vitro, MH7A and RAW 246.7 cells were treated with LPS and MSU. Serum uric acid, creatinine, and urea nitrogen levels were evaluated. Kidney and ankle joint pathology was observed via HE staining. Inflammatory signaling pathway proteins, epithelial-mesenchymal transition (EMT) pathway proteins, and uric acid metabolism-related proteins were detected by Western blot.
RESULTS: 1780 potential targets for gout treatment were identified, and 1039 target proteins corresponding to BQ's active ingredients were obtained. Pathway enrichment analysis revealed BQ improved gout mainly through inflammatory pathways. Experimental results showed BQ could reduce serum uric acid level and increase uric acid clearance rate by regulating the expression of adenosine deaminase (ADA), and organic anion transporter 1 (OAT1) and glucose transporter 9 (GLUT9) in HUA mice. BQ could improve renal function and injury by inhibiting the NLRP3 pathway in HUA mice' kidneys. Additionally, BQ could alleviate ankle joint swelling and synovial injury, inhibit the TLR4/NLRP3 pathway, and reduce levels of inflammatory factors including interleukin 6 (IL-6), interleukin 1β (IL-1β), and tumor necrosis factor-alpha (TNF-α) in AGA rats. The main component of BQ, brucine, could inhibit the activation of NLRP3/NF-κB pathway induced by MSU and reduce the expression level of inflammatory factors (IL-6, IL-1β, and TNF-α) in macrophages. Brucine could inhibit the activation of the EMT pathway and reduce the expression level of inflammatory factors (IL-6, TNF-α) in human fibroblast-like synoviocytes (MH7A cells) induced by MSU.
CONCLUSIONS: BQ effectively reduced serum uric acid levels, improved kidney and joint damage, and ameliorated the inflammatory response caused by MSU. Its main component, brucine, effectively improved the inflammatory response and reduced the invasive ability of synoviocytes induced by MSU.
A bed-leaving alarm care management system is composed of an information platform established in a network, multiple bed-leaving alarm devices, and an electronic device. The information platform includes a control module, a patient database, a facility database, and a bed-leaving information database. Each bed-leaving alarm device includes an alarm unit and a connection module. The alarm unit is used to sense the displacement status of a patient on a hospital bed and send a warning signal to the control module. The electronic device includes an application program interface, and a user can connect to the information platform through the application program interface, and can display a facility pairing option, a patient pairing option, and a bed-leaving setting operation. By setting various options, the user enables to operate and monitor the bed-leaving warning equipment via the network, and when the control module receives the warning signal, it will transmit the warning signal to the application program interface of the electronic device to generate a warning message.
Breast compression and/or immobilization during positron emission tomographic (PET) imaging has been called positron emission mammography, or "PEM," and the device used to perform the scan has been called a PEM Scanner. This protocol is designed as a prospective multi-center clinical trial to evaluate the role of high resolution PEM, used in combination with the radiotracer 2-\[F-18\]- fluorodeoxyglucose (FDG), in pre-surgical planning in women with newly diagnosed breast cancer who are considered candidates for breast conserving surgery (i.e. lumpectomy) after full workup with mammography, clinical breast exam, and additional US as would normally be performed. Participants will undergo both contrast enhanced MRI and PEM imaging. In order to control for potential bias in interpretation of the second examination (i.e. PEM or MRI), the order of interpretation of these examinations will be randomly assigned at study entry.The primary objective of the study is to determine changes in surgical management resulting from PEM or MRI or both, separately and in conjunction with conventional imaging and to determine whether these changes were appropriate (i.e. to excise malignancy) or inappropriate (e.g. wider excision or mastectomy for what proved to be benign disease).
Cancer causes important public health problems around the world and it is one of the most frequent cause of death overall. Among non-pharmacological treatment, physical exercise has shown improvements in different types of cancer and patients, but it is important to define the optimal dose. Our aim is to determine the effects of a concurrent training program and a nutritional management developed during radiotherapy treatment on physical performance and body composition. A patient with an oral cavity cancer will develop three sessions per week of concurrent training: resistance training included 9 standard exercises involving major muscle groups (4x8-12 RM), and cardiovascular training included a High-Intensity Interval Training (HIIT). Nutritional management will include a diet controlling macronutrients (\~4g/kg/day for carbohidrates, \~2g/kg/day for proteins, and \~1g/kg/day for fats), along with some nutritional supplements such as beta-hydroxybeta-methylbutyrate (HMB), arginine, glutamine, omega-3 fish oil concentrate, and BCAA's during training sessions. Intervention took place during radiotherapy period (7 weeks). We expect that body composition will remain invariable, and 1RM will increased. VO2max is expected to be almost the same, but intensity tolerated at maximum VO2max could be higher. If our results confirm that, we could conclude that a combination between resistance exercise and HIIT along with a nutritional management developed during radiotherapy could be effective to prevent muscle mass loss and muscle function decrease in a young patient with oral cavity cancer.
Obesity continues to be a prevalent health concern affecting every race of the American population. According to data from the World Health Organization, 54% of U.S. adults are overweight (body mass index (BMI) \>25 kg/m2 ) and 22% are obese (BMI \>30 kg/m2) (1). In addition, 25% of U.S. children are overweight or obese (1). Studies show that obese children are likely to become obese adults (2-5). Also, recent studies report significant years of life lost due to the impact of being an obese adult (6, 7). Thus, insights into the pathogenesis of childhood obesity and preventative measures are needed to combat the inevitable increase in worldwide incidence of obesity and its associated co-morbidities. Recent studies have identified a new gastroenteric hormone, ghrelin, as a long-term regulator of energy balance in humans (12). Ghrelin is a 28 amino acid acylated peptide which is an endogenous ligand of the growth hormone secretagogue receptor (GHS-R), a hypothalamic G-protein-coupled receptor (13). Enteroendocrine cells (X/A-like cells) of the stomach are the major site of ghrelin synthesis, although a minor proportion of ghrelin synthesis occurs in other sites such as the hypothalamus, pituitary, duodenum, jejunum and lung (14) (15, 16).

The hypothesis that hyperghrelinemia causes some of the features of PWS predicts that this disorder will be ameliorated (partially or completely) by lowering ghrelin levels. We have recently shown that the somatostatin agonist, octreotide, suppresses ghrelin levels in humans. If octreotide remains effective in longer term studies, the drug may become an adjuvant therapy, in addition to growth hormone, to control the insatiable appetite and morbid obesity seen in this condition.
BACKGROUND: Mitochondrial dysregulation in skeletal myocytes is considered a major factor in aged sarcopenia. In this study, we aimed to study the effects of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α) on Sestrin2-mediated mechanistic target of rapamycin complex 1 (mTORC1) in aged skeletal muscles.
METHODS: C2C12 myoblasts were stimulated by 50 μM 7β-hydroxycholesterol (7β-OHC) to observe the changes of DNA damage, mitochondrial membrane potential (Δψm), mitochondrial ROS and PGC-1α protein. The PGC-1α silence in the C2C12 cells was established by siRNA transfection. The levels of DNA damage, Δψm, mitochondrial ROS, Sestrin2 and p-S6K1/S6K1 proteins were observed after the PGC-1α silence in the C2C12 cells. Recombinant Sestrin2 treatment was used to observe the changes of DNA damage, Δψm, mitochondrial ROS and p-S6K1/S6K1 protein in the 7β-OHC-treated or PGC-1α siRNA-transfected C2C12 cells. Wild-type (WT) mice and muscle-specific PGC-1α conditional knockout (MKO) mice, including young and old, were used to analyse the effects of PGC-1α on muscle function and the levels of Sestrin2 and p-S6K1 in the white gastrocnemius muscles. Recombinant Sestrin2 was administrated to analyse its effects on muscle function in the old WT mice and old MKO mice.
RESULTS: 7β-OHC treatment induced DNA damage, mitochondrial dysfunction and decrease of PGC-1α protein in the C2C12 cells. PGC-1α silence also induced DNA damage and mitochondrial dysfunction in the C2C12 cells. Additionally, PGC-1α silence or 7β-OHC treatment decreased the levels of Sestrin2 and p-S6K1/S6K1 protein in the C2C12 cells. Recombinant Sestrin2 treatment significantly improved the DNA damage and mitochondrial dysfunction in the 7β-OHC-treated or PGC-1α siRNA-transfected C2C12 cells. At the same age, muscle-specific PGC-1α deficiency aggravated aged sarcopenia and decreased the levels of Sestrin2 and p-S6K1 in the white gastrocnemius muscles when compared to the WT mice. Recombinant Sestrin2 treatment improved muscle function and increased p-S6K1 levels in the old two genotypes.
CONCLUSION: This research demonstrates that PGC-1α participates in regulating mitochondrial function in aged sarcopenia through effects on the Sestrin2-mediated mTORC1 pathway.
PCT No. PCT/JP94/01901 Sec. 371 Date Jul. 10, 1995 Sec. 102(e) Date Jul. 10, 1995 PCT Filed Nov. 10, 1994 PCT Pub. No. WO95/13272 PCT Pub. Date May 18, 1995Chroman derivatives of the formula [I]    <IMAGE>  [I]  wherein R1 is a cyano, a nitro, a trihalomethyl, a trihalomethoxy or a halogen atom; R2 is a lower alkoxyalkyl, an aryloxyalkyl or a dialkoxyalkyl; R3 is a lower alkoxyalkyl or an aryloxyalkyl; R4 is a hydroxy, a formyloxy or a lower alkanoyloxy; X is N-H, an N-optionally substituted lower alkyl, an oxygen atom, a sulfur atom or a single bond; and Y is an optionally substituted aromatic ring residue or an optionally substituted heterocyclic residue, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The compound of the present invention and pharmaceutically acceptable salts thereof have selective and excellent coronary vasodilating action and extremely weak hypotensive action. Accordingly, it is possible to selectively increase the coronary blood flow without causing a sudden hypotention causative of tachycardia which has a detrimental effect on the heart, and they are useful as a coronary vasodilator, in particular, an agent for the prophylaxis and treatment of cardiovascular disorders such as angina pectoris and heart failure.
INTRODUCTION: Dual immunostaining for p16/Ki67 is FDA-approved for use on liquid-based cervical cytology specimens; however, the utility of dual staining in anal cytology especially for ASCUS risk stratification is not well established.
METHODS: We investigated dual staining performance on anal cytology specimens and correlated with subsequent cytologic interpretation, high-risk HPV status, and anal biopsy results. Dual staining for p16/Ki-67 was performed on all liquid-based anal cytology specimens from December 2021 to June 2022 (n = 43).
RESULTS: Three patients had high grade squamous intraepithelial lesion (HSIL/AIN2-3) on biopsy; dual staining was positive in all three cases. All HR-HPV negative cases were negative for dual staining. Among the 12 ASCUS samples with subsequent anal biopsy results all also had HR-HPV testing. Due to small sample size of cases with squamous intraepithelial lesion (SIL) diagnosed on biopsy, the sensitivity and positive predictive value was not calculated. However, the specificity and negative predictive value of p16/Ki-67 dual staining for SIL of any grade on biopsy were 1 (95% CI: 0.66-1) and 0.9 (95% CI: 0.65-0.97) respectively, whereas the specificity and negative predictive value of HR-HPV testing for SIL of any grade on biopsy were 0.44 (95% CI: 0.14-0.79) and 0.8 (95% CI: 0.41-0.96) respectively.
CONCLUSION: Dual p16/Ki-67 staining indicates transforming HPV infection and could help serve as an ancillary test for risk stratification for atypical anal cytology specimens. Among ASCUS samples, dual staining was specific for SIL of any grade with a high negative predictive value and therefore could be useful in clinical practices with limited availability for follow-up care.
PROBLEM TO BE SOLVED: To obtain a solid preparation containing loxoprofen sodium and having decreased adhesiveness. SOLUTION: The solid preparation contains an additive such as microcrystalline cellulose, hydroxypropyl cellulose having low substitution degree, lactose or magnesium stearate compounded in an amount to give a total water-feeding capacity of >=1.7, preferably >=2.0. The mixture is prepared in the form of a solid preparation such as tablet, capsule, granule or powder e.g. by dry or wet-mixing method. The addition of the additive in an amount to get a total water-feeding capacity exceeding a specific level effectively prevents the blocking of the composition caused by the adhesion to the machine in tableting or encapsulation, the adhesion of the drug component to a vessel and the agglomeration of drugs. Loxoprofen sodium has a chemical name of 2-[4-(2- oxocyclopentan-1-ylmethyl)phenyl]propionic acid sodium salt and is useful as an analgesic anti-inflammatory antipyretic agent.
The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
Amphipathic lyric peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lyric peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lyric peptide kills colts with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes). Lysis of tumor cells is rapid. The two components -the ligand and the lyric peptide- may optionally be administered as a fusion peptide, or they may be administered separately, with the ligand administered slightly before the lyric peptide, to activate cells with receptors for the ligand, and thereby make those cells susceptible to lysis by the lyric peptide. The compounds may be used in gene therapy to treat malignant or non-malignant tumors, and other diseases caused by clones or populations of "normal" host cells bearing specific receptors (such as lymphocytes), because genes encoding a lyric peptide or encoding a lyric peptide/peptide hormone fusion may readily be inserted into hematopoietic stem cells or myeloid precursor cells.
Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
The invention discloses an application of Chukrasone A in the preparation of anti-diabetic medicines. The application of the Chukrasone A has the advantages of providing bran-new choice and idea for the existing anti-diabetic medicines, widening the choice field of the anti-diabetic medicines and contributing to the development of the technical field. The application of the Chukrasone A is proven to have an obvious anti-diabetic effect. The Chukrasone A is a compound with a definite chemical structure. The application of the Chukrasone A in the preparation of the anti-diabetic medicines is disclosed for the first time. As the skeleton type of the Chukrasone A belongs to a bran-new skeleton type and the Chukrasone A has unexpected strong activity on the prevention and treatment of diabetes, the possibility that other compounds provide revelation does not exist. The Chukrasone A has prominently substantial characteristics and meanwhile has remarkably progressive significance when being used for treating the diabetes.
The invention provides an HB-NC4 recombinant protein, a preparation method and application thereof, belonging to the technical field of biological medicine, wherein the recombinant protein is formed by recombining an N-terminal non-collagen structural domain 4 and an HB heparin binding structural domain of NC4 human collagen IX. The amino acid residue sequence of the recombinant protein is shown as SEQ ID NO. 1. The nucleotide sequence for coding the recombinant protein is shown as SEQ ID NO.3, or the sequence with the degeneracy of the genetic code. In the nucleotide sequence for coding the recombinant protein, the nucleotide sequence for coding the heparin binding structural domain is shown as SEQ ID NO.4, the nucleotide sequence for coding the N-terminal non-collagen structural domain 4 of the human collagen IX is shown as SEQ ID NO.5, or the sequence with the degeneracy of the genetic code. And a preparation method of the HB-NC4 fusion protein. The HB-NC4 fusion protein retains the complement inhibition activity of the N-terminal structural domain 4 of the collagen IX, can directly target and retain cartilage, and greatly improves the targeting property and the retention time of the fusion protein.
Multisystem inflammatory syndrome in children (MIS-C) has been reported in patients with inborn errors of immunity (IEI), providing insights into disease pathogenesis. Here, we present the first case of MIS-C in a child affected by Wiskott-Aldrich syndrome (WAS) gene mutation, elucidating underlying predisposing factors and the involved inflammatory pathways. Genetic analysis revealed a frameshift truncating variant in the WAS gene, resulting in WAS protein expression between mild and severe forms, despite a clinical phenotype resembling X-linked thrombocytopenia (XLT). IL-1β secretion by LPS-stimulated peripheral blood mononuclear cells from patient during MIS-C was lower compared to healthy subjects but increased during follow-up. Conversely, the percentage of ASC (apoptosis-associated speck-like protein containing a CARD) specks in the patient's circulating monocytes during the acute phase was higher than in healthy subjects. The type I interferon (IFN) signature during MIS-C was normal, in contrast to the raised IFN signature measured far from the acute event. This case supports the association of IEI with MIS-C, potentially linked to delayed immune responses to SARS-CoV-2. The XLT phenotype underlies a subclinical immunodysregulation involving the NLRP3 inflammasome and the type-I IFN response.
PCT No. PCT/FR89/00452 Sec. 371 Date May 9, 1990 Sec. 102(e) Date May 9, 1990 PCT Filed Sep. 8, 1989 PCT Pub. No. WO90/02774 PCT Pub. Date Mar. 22, 1990.An aqueous gel based on hyaluronic acid and on deoxyribonucleic acid usable in cosmetics, and a method of preparation. The invention relates to an aqueous gel formed by a homogeneous mix of: a) an alkaline salt or an ammonium salt of hyaluronic acid in the form of an aqueous gel; b) a mineral or organic salt of high molecular weight deoxyribonucleic acid in the form of an aqueous gel; c) at least one hydrophilic polymer having the property of forming aqueous film-forming gels. Application to the preparation of masks in cosmetics.